{
  "abstract": "The persistent absence of disease-modifying therapy for recurrent acute pancreatitis (RAP) and chronic pancreatitis (CP) represents one of the more conspicuous therapeutic gaps in gastroenterology. Despite substantial advances in delineating the molecular and cellular mechanisms that govern pancreatic injury—including disordered calcium signalling, mitochondrial dysfunction, immune activation and fibrogenesis—clinical management remains largely anchored in supportive care rather than targeted pharmacologic intervention. For patients with RAP, this therapeutic inertia carries durable consequences: recurrent inflammatory episodes herald progression to CP with irreversible structural damage, lifelong metabolic and functional sequelae, pancreatic cancer risk and poor quality of life. Against this backdrop, the repurposing of established drugs presents an intellectually and pragmatically attractive strategy, offering the possibility of accelerated translation through agents with biological plausibility and known safety profiles. That such approaches have yet to meaningfully alter clinical trajectories suggests that the central barrier to progress may lie less in pharmacology than in how pancreatitis is defined, phenotyped and studied.",
  "authors": [
    {
      "affiliations": [
        "Division of Gastroenterology, Hepatology, and Nutrition, University of Florida, Gainesville, Florida, USA"
      ],
      "name": "Christopher E Forsmark"
    }
  ],
  "title": "Are the drugs already on the shelf? Repurposing therapy for pancreatitis",
  "uid": "90155a9a-cb58-5fa3-be9b-fc20a0511f3f"
}